Patents Assigned to Genentech
  • INHIBITION OF TUMOR METASTASIS
    Publication number: 20140234312
    Abstract: The invention provides Nrp2 antagonists, such as anti-Nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.
    Type: Application
    Filed: June 11, 2013
    Publication date: August 21, 2014
    Applicant: GENENTECH, INC.
    Inventors: Yan Wu, Wei-Ching Liang, Ryan Jefferson Watts, Anil Durgadas
  • METHODS AND COMPOSITIONS FOR MODULATING THE Wnt PATHWAY
    Publication number: 20140235820
    Abstract: The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6.
    Type: Application
    Filed: April 29, 2014
    Publication date: August 21, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric Bourhis, Andrea Cochran, Yingnan Zhang
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20140235828
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: December 11, 2013
    Publication date: August 21, 2014
    Applicants: AIMM THERAPEUTICS B.V., GENENTECH, INC.
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8809331
    Abstract: Specific Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein m, X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 19, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet L. Gunzner-Toste, Daniel Shore, Zachary Kevin Sweeney, Shumei Wang, Guiling Zhao
  • HUMANIZED ANTI-CMET ANTAGONISTS
    Publication number: 20140227258
    Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: March 14, 2014
    Publication date: August 14, 2014
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
  • NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20140227299
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 14, 2014
    Applicant: GENENTECH, INC.
    Inventors: Robert L. Cohen, Edward HyungSuk Ha, Mark E. Reynolds
  • Pharmaceutical compounds
    Patent number: 8802670
    Abstract: Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: August 12, 2014
    Assignees: F. Hoffmann-La Roche AG, Genentech, Inc.
    Inventors: Adrian Folkes, Stephen Shuttleworth, Irina Chuckowree, Sally Oxenford, Nan Chi Wan, Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Bing-Yan Zhu
  • Pyrrolidine derivatives
    Patent number: 8802665
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: August 12, 2014
    Assignee: Genentech, Inc.
    Inventors: David Banner, Wolfgang Haap, Thomas Luebbers, Jens-Uwe Peters
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8802674
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: August 12, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet Gunzner-Tate, Daniel Shore, Zachary Kevin Sweeney, Shumei Wang, Guiling Zhao
  • RNA interference modulators of hedgehog signaling and uses thereof
    Patent number: 8802639
    Abstract: The instant application relates to methods and reagents for modulating the Hedgehog signaling pathway using RNA interference technology (RNAi). The application provides potential targets of the Hedgehog RNAi, methods to identify additional Hedgehog signaling pathway components, methods to inhibit Hedgehog signaling targets using siRNA, and their uses in the treatment of a number of disease conditions.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: August 12, 2014
    Assignees: Curis, Inc., Genentech, Inc.
    Inventor: David A. Bumcrot
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE
    Publication number: 20140221386
    Abstract: The invention provides A combination of a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: August 7, 2014
    Applicant: GENENTECH, INC.
    Inventors: Michelle Nannini, Deepak Sampath
  • ALKYLATED PIPERAZINE COMPOUNDS
    Publication number: 20140221365
    Abstract: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating cancer mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: GENENTECH, INC.
    Inventors: James John Crawford, Wendy B. Young
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8796296
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 5, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Mark Chambers, Bryan K. Chan, Anthony Estrada, Zachary Kevin Sweeney
  • Neuropilin antagonists
    Patent number: 8795660
    Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 5, 2014
    Assignee: Genentech, Inc.
    Inventors: Ryan J. Watts, Yan Wu
  • METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
    Publication number: 20140212411
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 31, 2014
    Applicants: GENENTECH, INC., IMMUNOGEN, INC.
    Inventors: Walter BLATTLER, Ralph SCHWALL, Mark SLIWKOWSKI, Sharon ERICKSON, Ravi V.J. CHARI
  • Humanized Anti-Factor D Antibodies And Uses Thereof
    Publication number: 20140212433
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 31, 2014
    Applicant: Genentech, Inc.
    Inventors: ARTHUR HUANG, ROBERT KELLEY, HENRY LOWMAN, MENNO VAN LOOKEREN CAMPAGNE, CHARLES WINTER
  • METHODS FOR USE WITH BAFF ANTAGONISTS
    Publication number: 20140213470
    Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.
    Type: Application
    Filed: November 21, 2013
    Publication date: July 31, 2014
    Applicants: GENENTECH, INC., BIOGEN IDEC MA INC.
    Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
  • PCSK9-BINDING POLYPEPTIDES AND METHODS OF USE
    Publication number: 20140212431
    Abstract: The invention provides PCSK9-binding polypeptides and methods of using the same.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 31, 2014
    Applicant: GENENTECH, INC.
    Inventors: Daniel K. Kirchhofer, Yingnan Zhang, Andrew Scott Peterson, Wei Li, Monica Kong-Beltran, Lijuan Zhou
  • Aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 8791130
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: July 29, 2014
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Mark Chambers, Bryan K. Chan, Anthony Estrada, Zachary Kevin Sweeney
  • Cross-reactive and bispecific anti-IL-17A/F antibodies
    Patent number: 8790642
    Abstract: The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: July 29, 2014
    Assignee: Genentech, Inc.
    Inventors: Yongmei Chen, Yan (Helen) Hu, Wenjun Ouyang, Scott Stawicki, Yan Wu